IgG targeting antigenically novel SARS-CoV-2 receptor binding domain (RBD) trended higher in G1m1,17<sup>+/+</sup> vaccinees, facilitating increased RBD-specific FcγR2a-R131 and FcγR2b binding.<h4>Conclusion</h4>Primary COVID-19 vaccination induced increased S2-specific IgG in G1m1,17<sup>+/+</sup> vaccinees, facilitating enhanced anti-viral FcγR engagement and suggesting immunogenetics may be a valuble consideration for next-generation vaccine design. This evidence concerns the gene FCGR2A and COVID-19.